Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in riā¦ read more
Healthcare
Drug ManufacturersāGeneral
53 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$47.15
Price-0.17%
-$0.08
1Y
Price
Market Cap
$95.971b
Large
Price/Earnings 3y Avg5y Avg
18.9x
Premium
Premium
Financials Overview
Key metrics over the past few years+26.8%
EBITDA Margin+10.7%
Net Profit Margin+29.0%
Free Cash Flow MarginRevenue
$47.704b
-1.2%
1y CAGR+1.2%
3y CAGR+0.8%
5y CAGREarnings
$5.049b
+156.4%
1y CAGR-9.4%
3y CAGR-9.4%
5y CAGREPS
$2.48
+156.2%
1y CAGR-9.0%
3y CAGR-8.1%
5y CAGRBook Value
$17.489b
$94.676b
Assets$77.187b
Liabilities$50.929b
DebtDebt to Assets
53.8%
3.4x
Debt to EBITDAFree Cash Flow
$14.578b
+4.6%
1y CAGR+6.9%
3y CAGR-0.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company